3van Himbergen TM, Matthan NR, Resteghini NA, et al. Compari- son of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers [ J ]. J Lip- id Res,2009,50(4):730 -739.
4Turley SD, Dietschy JM. The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma choles- terol level[J]. Prev Cardiol, 2003, 6(1) : 29-33.
5Tremblay A J, Lamarche B, Lemelin V, et al. Atorvastatin increa- ses intestinal expression of NPC1 L! in hyperlipidemic men [ J]. J Lipid Res, 2011,52 ( 3 ) :558-565.
6Kajinami K, Takekoshi N. Cholesterol absorption inhibitors in de- velopment as potential therapeutics [ J ]. Expert Opin Investig Drugs ,2002,11 (6) : 831-835.
7Mieninen TA. Cholesterol absorption inhibition : a strategy for cho- lesterol-lowering therapy [ J ]. Int J Clin Pract, 2001,55 ( 10 ) : 710 - 716.
8Roeters van Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study [ J ]. Curr Med Res Opin,2008,24 ( 3 ) :685-694.
9Wierzbicki AS, Doherty E, Lumb PJ, et al. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hy- perlipidaemias [ J ]. Curr Med Res Opin, 2005,21 (3) :333-338.
10Howard BV, Roman M J, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes. The SANDS randomized trial [ J ]. JAMA, 2008, 299 (14) : 1678-1689.
